<DOC>
	<DOCNO>NCT01018550</DOCNO>
	<brief_summary>The primary objective determine AMG 853 effective compare placebo measure change Asthma Control Questionnaire ( ACQ ) composite symptom score baseline week 12 .</brief_summary>
	<brief_title>AMG 853 Phase 2 Study Subjects With Inadequately Controlled Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Males females 18 65 year age Percent predict FEV1 ≥ 50 % ≤ 80 % At least 12 % reversibility prebronchodilator FEV1 Inhaled corticosteroid ( ICS ) ≥ 200 ≤ 1000 µg/day fluticasone equivalent . Ongoing asthma symptom ACQ score ≥ 1.5 point History chronic obstructive pulmonary disease chronic pulmonary condition asthma Any uncontrolled , clinically significant systemic disease Respiratory infection within 4 week screen visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>